Arzeda
Seattle, US · Delaware corporation · 78 employees on LinkedIn · 6 known investors
Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software. The company operates in the computational biology and protein engineering field.
Founders & leadership
AZ
Alexandre ZanghelliniinCo-founder & CEO
EA
Eric AlthoffCo-founder
BB
Bill BauminNamed on SEC filing
AB
Andrew BanNamed on SEC filing
DG
Daniela GrabsNamed on SEC filing
DB
David Baker
Board
JK
Investors · 6
Reported raises · per SEC filings
Form D private placements$82.9M disclosed across 6 rounds · 2017–2025
▶$4.5MraisedSep 2025 · 6 investors · OtherRule 506(b)
▶$4.5MraisedSep 2025 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Larry PageDirector
- Yanniv DoroneDirector
- William BaumDirector
- Doug CameronDirector
- Sanjay PalExecutive Officer
- Alexandre ZanghelliniExecutive Officer, Director, Promoter
- Brian LoebDirector
- Daniela GrabsDirector
- Offering amount
- $25M
- Amount sold
- $4.5M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37.9MraisedAug 2024 · 21 investors · OtherRule 506(b)
▶$37.9MraisedAug 2024 · 21 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Daniela GrabsExecutive Officer, Director
- Yanniv DoroneDirector
- Brian LoebDirector
- Larry PageDirector
- William BaumDirector
- Sanjay PalExecutive Officer
- Doug CameronDirector
- Alexandre ZanghelliniExecutive Officer, Director, Promoter
- Offering amount
- $38M
- Amount sold
- $37.9M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.7MraisedJul 2021 · 14 investors · OtherRule 506(b)
▶$25.7MraisedJul 2021 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Brian LoebDirector
- Doug CameronDirector
- William BaumDirector
- Alexandre ZanghelliniExecutive Officer, Director, Promoter
- Daniela GrabsExecutive Officer, Director
- Jeffrey KlunzingerDirector
- Offering amount
- $38.8M
- Amount sold
- $25.7M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedNov 2020 · 3 investors · OtherRule 506(b)
▶$3.3MraisedNov 2020 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Alexandre ZanghelliniExecutive Officer, Director, Promoter
- Jeff KlunzingerDirector
- Daniela GrabsExecutive Officer, Director
- Bill BaumDirector
- Doug CameronDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedNov 2019 · 1 investors · OtherRule 506(b)
▶$1MraisedNov 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Alexandre ZanghelliniExecutive Officer, Director, Promoter
- Eric AlthoffExecutive Officer, Director, Promoter
- Jeff KlunzingerDirector
- Bill BaumDirector
- Andrew BanExecutive Officer
- Daniela GrabsExecutive Officer
- Offering amount
- $3M
- Amount sold
- $1M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.5MraisedJul 2017 · 5 investors · OtherRule 506(b)
▶$10.5MraisedJul 2017 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jeff KlunzingerDirector
- Daniela GrabsExecutive Officer, Promoter
- Alexandre ZanghelliniExecutive Officer, Director, Promoter
- Bill BaumDirector
- Eric AlthoffExecutive Officer, Director, Promoter
- Offering amount
- $12.2M
- Amount sold
- $10.5M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Arzeda went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Arzeda for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseOffice for Chemical and Biological Defense | Phase II | 2022 | $1.1M |
| National Science Foundation | Phase II | 2015 | $744.8K |
| Department of Energy | Phase I | 2015 | $224.9K |
| National Science Foundation | Phase II | 2013 | $500K |
| National Science Foundation | Phase ISTTR | 2013 | $225K |
| National Science Foundation | Phase I | 2011 | $150K |
| National Science Foundation | Phase I | 2011 | $149.9K |
| National Science Foundation | Phase I | 2010 | $149.2K |
| Department of Agriculture (USDA) | Phase I | 2010 | $90K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Arzeda do?
- Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software. The company operates in the computational biology and protein engineering field.
- Who founded Arzeda?
- Arzeda was founded by Alexandre Zanghellini, Eric Althoff.
- Who are Arzeda's investors?
- Arzeda's investors include Circulate Capital, Sofinnova Partners, Sustainable Conversion Ventures, Fall Line Capital, OS Fund, Universal Materials Incubator.
- How much funding has Arzeda raised?
- Arzeda has disclosed $82.9M raised across 6 rounds.
- Where is Arzeda headquartered?
- Arzeda is headquartered in Seattle, US.